Effectiveness of Ayurvedic intervention in Primary Open Angle Glaucoma (Kaphaja Adhimantha) - A Case Study
Abstract
Glaucoma is a diverse group of disorders affecting the eye with a common characteristic potentially progressive optic neuropathy that is determined by both structural changes and functional deficit in which IOP is a key modifiable factor. In Primary Open Angle Glaucoma (POAG), IOP independent mechanisms of glaucomatous nerve damage and visual field loss with unobstructed angle of anterior chamber is observed. The patient has reported gradual diminution of peripheral aspect of visual field (Rt. eye - 6/12 and Lt. eye - 6/12 on Snellen’s distant vision chart) in both eyes for 2 years. There was marked peripheral field defect on both confrontation test and perimetry visual field analysis test. The disease shows clinical similarity with Kaphaja Adhimantha, a disease affecting the whole eye mentioned in Susruta Samhita and Ashtanga Hrudaya. It is a chronic disease comes under life style related disorder. Dukhena Roopam Pasyathi (distorted image or constricted visual field), Sirodukha (headache), Srava (watering), Kandu (itching), Pamsupoornatha (foreign body sensation), Aviladarsana (diminished vision) and Gourava (heaviness of eye and head) are the clinical findings explained in the context of Kaphaja Adhimantha. These clinical findings mentioned in classical literature show resemblance with POAG. The meticulous deployment of kaphaja AbhisyandhaAdhimantha treatment protocol can be used to prevent the progression of ganglionic damage and preservation of eye sight. The logical interpretation on the basis of both subjective and objective clinical findings concluded the diagnosis as Kaphaja Adhimantha and treatment principle adopted was Apatharpana, Kaphahara, Abhisyandhahara and Srothovisodhana. After treatment his vision has improved as 6/6 in both eyes and remarkable change in visual field analysis. The study discusses about the effectiveness of Ayurvedic management in POAG.
Downloads
References
Facts about Glaucoma search by www.who.int/blindness/causes/priority/en/index6.ht ml
Kanski JJ, Clinical Ophthalmology, Elsevier publication; 8thedition, 2016; p.307
Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am 2005; 18 (3): 383–95
Johnson M. What controls aqueous humour outflow resistance? Exp Eye Res. 2006;82(4):545–57.[PMC free article] [PubMed]
Khurana A.K, Comprehensive Ophthalmology, 6th edition, New Delhi: New Age International, 2017; p.229
George R, Ve RS, Vijaya L. Glaucoma in India: Estimated burden of disease. J Glaucoma. 2010; 19:391– 7. [PubMed]
Beidoe G, Mousa SA. Current primary open-angle glaucoma treatments and future directions. Clin Ophthalmol. 2012; 6:1699–1707. [PMC free article] [PubMed]
Susrutha with the Nibabdhasangraha commentary of Sri Dalhanacharya. Uttaratantra 6th chapter 16-17 sloka. Vaidya Jadavji Trikamji Acharya (ed). Susrutha Samhitha, re-print edition ed. Varanasi: Krishnadas Acadamy; 2015. pp. 603.
Vagbhata. Suthrasthana 24th chapter-16th sloka. Bhishagacharya Harisastri Paradakara Vaidya (ed). Ashtanga Hrudayam with commentaries of (Sarvangasundara) of Arunadutta and (Ayurveda Rasayana) of Hemadri, Reprint tenth edition ed. Varanasi: Chaukhambha orientalia; 2011. pp. 309.
Susrutha with the Nibabdha Sangraha commentary of Sri Dalhanacharya. Uttaratantra 11th chapter 1-4 sloka. Vaidya Jadavji Trikamji Acharya (ed). Susrutha Samhitha, re-print edition ed. Varanasi: Krishnadas Acadamy; 2015. pp. 615
Journal of Ayurveda and Integrated Medical Sciences (JAIMS) retains the copyright of the contents of this journal but grant the readers the right to use the contents with terms and conditions under a creative common attribution licenses 4 of Attribution, Share Alike and Non-commercial type (CC BY-NC-SA) that allows copy, distribute, display, and perform the work and make derivative works based on it only for non-commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.